How much profit has Dr Hoenle made this year?
Dr Hoenle has made -1.47 M EUR this year.
Dr Hoenle Net Income 2024
Dr Hoenle Net Income
-1.47 M EUR
Ticker
HNL.DE
ISIN
DE0005157101
WKN
515710
In 2024, Dr Hoenle's profit amounted to -1.47 M EUR, a -86.65% increase from the -11.01 M EUR profit recorded in the previous year.
The Dr Hoenle Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2030e | - |
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | 6.15 |
| 2025e | 2.63 |
| 2024e | -1.47 |
| 2023 | -11.01 |
| 2022 | -13.36 |
| 2021 | -4.82 |
| 2020 | 5.68 |
| 2019 | 12.48 |
| 2018 | 21.74 |
| 2017 | 10.43 |
| 2016 | 8.28 |
| 2015 | 10.13 |
| 2014 | 6.3 |
| 2013 | 6.6 |
| 2012 | 5 |
| 2011 | 6.9 |
| 2010 | 4.6 |
| 2009 | -4.2 |
| 2008 | 4.4 |
| 2007 | 3 |
| 2006 | 2.8 |
| 2005 | 2.6 |
| 2004 | 2.2 |
Dr Hoenle Revenue, EBIT, Net Income DE0005157101 · 515710
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Dr Hoenle, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dr Hoenle from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dr Hoenle’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Dr Hoenle. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Dr Hoenle’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Dr Hoenle’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dr Hoenle’s growth potential.
Dr Hoenle Revenue, EBIT and net profit per share
| Date | Dr Hoenle Revenue | Dr Hoenle EBIT | Dr Hoenle Net Income |
|---|---|---|---|
| 2030e | 176.67 M undefined | 0 undefined | 0 undefined |
| 2029e | 168.25 M undefined | 25.27 M undefined | 0 undefined |
| 2028e | 160.23 M undefined | 24.06 M undefined | 0 undefined |
| 2027e | 151.1 M undefined | 22.66 M undefined | 0 undefined |
| 2026e | 122.06 M undefined | 10.3 M undefined | 6.15 M undefined |
| 2025e | 111.15 M undefined | 5.45 M undefined | 2.63 M undefined |
| 2024e | 98.53 M undefined | -151,500 undefined | -1.47 M undefined |
| 2023 | 106.34 M undefined | -9.19 M undefined | -11.01 M undefined |
| 2022 | 116.09 M undefined | 4.01 M undefined | -13.36 M undefined |
| 2021 | 115.17 M undefined | 165,000 undefined | -4.82 M undefined |
| 2020 | 93.88 M undefined | 8.89 M undefined | 5.68 M undefined |
| 2019 | 107.75 M undefined | 17.02 M undefined | 12.48 M undefined |
| 2018 | 126.49 M undefined | 30.84 M undefined | 21.74 M undefined |
| 2017 | 101.93 M undefined | 15.51 M undefined | 10.43 M undefined |
| 2016 | 93.42 M undefined | 12.37 M undefined | 8.28 M undefined |
| 2015 | 92.17 M undefined | 12.88 M undefined | 10.13 M undefined |
| 2014 | 82.1 M undefined | 9.6 M undefined | 6.3 M undefined |
| 2013 | 77.3 M undefined | 8 M undefined | 6.6 M undefined |
| 2012 | 72.1 M undefined | 9.2 M undefined | 5 M undefined |
| 2011 | 72.7 M undefined | 11.3 M undefined | 6.9 M undefined |
| 2010 | 56.5 M undefined | 5.5 M undefined | 4.6 M undefined |
| 2009 | 47.1 M undefined | -3.9 M undefined | -4.2 M undefined |
| 2008 | 50.4 M undefined | 5.6 M undefined | 4.4 M undefined |
| 2007 | 26.7 M undefined | 4.3 M undefined | 3 M undefined |
| 2006 | 24.3 M undefined | 3.4 M undefined | 2.8 M undefined |
| 2005 | 23.3 M undefined | 3.5 M undefined | 2.6 M undefined |
| 2004 | 22.9 M undefined | 2.9 M undefined | 2.2 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 22.9 M EUR | 2.9 M EUR | 2.2 M EUR |
| 2005 | 23.3 M EUR | 3.5 M EUR | 2.6 M EUR |
| 2006 | 24.3 M EUR | 3.4 M EUR | 2.8 M EUR |
| 2007 | 26.7 M EUR | 4.3 M EUR | 3 M EUR |
| 2008 | 50.4 M EUR | 5.6 M EUR | 4.4 M EUR |
| 2009 | 47.1 M EUR | -3.9 M EUR | -4.2 M EUR |
| 2010 | 56.5 M EUR | 5.5 M EUR | 4.6 M EUR |
| 2011 | 72.7 M EUR | 11.3 M EUR | 6.9 M EUR |
| 2012 | 72.1 M EUR | 9.2 M EUR | 5 M EUR |
| 2013 | 77.3 M EUR | 8 M EUR | 6.6 M EUR |
| 2014 | 82.1 M EUR | 9.6 M EUR | 6.3 M EUR |
| 2015 | 92.17 M EUR | 12.88 M EUR | 10.13 M EUR |
| 2016 | 93.42 M EUR | 12.37 M EUR | 8.28 M EUR |
| 2017 | 101.93 M EUR | 15.51 M EUR | 10.43 M EUR |
| 2018 | 126.49 M EUR | 30.84 M EUR | 21.74 M EUR |
| 2019 | 107.75 M EUR | 17.02 M EUR | 12.48 M EUR |
| 2020 | 93.88 M EUR | 8.89 M EUR | 5.68 M EUR |
| 2021 | 115.17 M EUR | 165,000 EUR | -4.82 M EUR |
| 2022 | 116.09 M EUR | 4.01 M EUR | -13.36 M EUR |
| 2023 | 106.34 M EUR | -9.19 M EUR | -11.01 M EUR |
| 2024e | 98.53 M EUR | -151,500 EUR | -1.47 M EUR |
| 2025e | 111.15 M EUR | 5.45 M EUR | 2.63 M EUR |
| 2026e | 122.06 M EUR | 10.3 M EUR | 6.15 M EUR |
| 2027e | 151.1 M EUR | 22.66 M EUR | 0 EUR |
| 2028e | 160.23 M EUR | 24.06 M EUR | 0 EUR |
| 2029e | 168.25 M EUR | 25.27 M EUR | 0 EUR |
| 2030e | 176.67 M EUR | 0 EUR | 0 EUR |
Dr Hoenle stock margins DE0005157101 · 515710
The Dr Hoenle margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dr Hoenle. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dr Hoenle.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Dr Hoenle's sales revenue. A higher gross margin percentage indicates that the Dr Hoenle retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Dr Hoenle's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Dr Hoenle's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dr Hoenle's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dr Hoenle. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dr Hoenle's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Dr Hoenle Margin History
| Dr Hoenle Gross margin | Dr Hoenle Profit margin | Dr Hoenle EBIT margin | Dr Hoenle Profit margin |
|---|---|---|---|
| 2030e | 50.17 % | 0 % | 0 % |
| 2029e | 50.17 % | 15.02 % | 0 % |
| 2028e | 50.17 % | 15.02 % | 0 % |
| 2027e | 50.17 % | 15 % | 0 % |
| 2026e | 50.17 % | 8.44 % | 5.04 % |
| 2025e | 50.17 % | 4.91 % | 2.37 % |
| 2024e | 50.17 % | -0.15 % | -1.49 % |
| 2023 | 50.17 % | -8.65 % | -10.35 % |
| 2022 | 54.6 % | 3.45 % | -11.51 % |
| 2021 | 60.21 % | 0.14 % | -4.19 % |
| 2020 | 64.49 % | 9.47 % | 6.05 % |
| 2019 | 67.59 % | 15.8 % | 11.58 % |
| 2018 | 67.51 % | 24.38 % | 17.19 % |
| 2017 | 64.56 % | 15.22 % | 10.23 % |
| 2016 | 64.07 % | 13.24 % | 8.86 % |
| 2015 | 64.01 % | 13.97 % | 10.99 % |
| 2014 | 64.07 % | 11.69 % | 7.67 % |
| 2013 | 62.61 % | 10.35 % | 8.54 % |
| 2012 | 63.11 % | 12.76 % | 6.93 % |
| 2011 | 62.45 % | 15.54 % | 9.49 % |
| 2010 | 60.35 % | 9.73 % | 8.14 % |
| 2009 | 54.78 % | -8.28 % | -8.92 % |
| 2008 | 58.13 % | 11.11 % | 8.73 % |
| 2007 | 66.67 % | 16.1 % | 11.24 % |
| 2006 | 65.84 % | 13.99 % | 11.52 % |
| 2005 | 64.38 % | 15.02 % | 11.16 % |
| 2004 | 61.14 % | 12.66 % | 9.61 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 61.14 % | 12.66 % | 9.61 % |
| 2005 | 64.38 % | 15.02 % | 11.16 % |
| 2006 | 65.84 % | 13.99 % | 11.52 % |
| 2007 | 66.67 % | 16.1 % | 11.24 % |
| 2008 | 58.13 % | 11.11 % | 8.73 % |
| 2009 | 54.78 % | -8.28 % | -8.92 % |
| 2010 | 60.35 % | 9.73 % | 8.14 % |
| 2011 | 62.45 % | 15.54 % | 9.49 % |
| 2012 | 63.11 % | 12.76 % | 6.93 % |
| 2013 | 62.61 % | 10.35 % | 8.54 % |
| 2014 | 64.07 % | 11.69 % | 7.67 % |
| 2015 | 64.01 % | 13.97 % | 10.99 % |
| 2016 | 64.07 % | 13.24 % | 8.86 % |
| 2017 | 64.56 % | 15.22 % | 10.23 % |
| 2018 | 67.51 % | 24.38 % | 17.19 % |
| 2019 | 67.59 % | 15.8 % | 11.58 % |
| 2020 | 64.49 % | 9.47 % | 6.05 % |
| 2021 | 60.21 % | 0.14 % | -4.19 % |
| 2022 | 54.6 % | 3.45 % | -11.51 % |
| 2023 | 50.17 % | -8.65 % | -10.35 % |
| 2024e | 50.17 % | -0.15 % | -1.49 % |
| 2025e | 50.17 % | 4.91 % | 2.37 % |
| 2026e | 50.17 % | 8.44 % | 5.04 % |
| 2027e | 50.17 % | 15 % | 0 % |
| 2028e | 50.17 % | 15.02 % | 0 % |
| 2029e | 50.17 % | 15.02 % | 0 % |
| 2030e | 50.17 % | 0 % | 0 % |
Dr Hoenle Aktienanalyse
What does Dr Hoenle do?
The Dr Hoenle AG is a traditional company specializing in the production and distribution of UV systems, industrial drying systems, adhesives, and coating systems. It was founded in 1972 by Dr. Rolf Hoenle in Gräfelfing near Munich and has an international customer base. The history of Dr Hoenle AG began in the 1960s when Dr. Hoenle recognized the importance of UV technology for the industry and intensified his research in this area. In the 1970s, the company built its first UV exposure systems and thus developed into a leading manufacturer of UV systems. Dr Hoenle AG has divided its activities into various divisions. The UV Technology and Process Engineering department specializes in the production of UV systems. The UV systems are used in various industries, such as the paint, coating, automotive, paper, and printing industries. The UV systems can be used for curing coatings, disinfecting surfaces, and drying paints and varnishes. The industrial drying systems division specializes in the design and construction of drying systems for materials. The drying systems are used, among other things, in the textile industry, packaging and label printing, and food processing. The Adhesives and Coating Systems department produces innovative adhesives and coatings for various applications. The products are used, for example, in the automotive and electronics industries, as well as in construction and furniture manufacturing. Dr Hoenle AG has a wide range of products in its portfolio. The UV systems are available in various designs and sizes and can be customized to meet the individual needs of customers. The industrial drying systems are available in various designs, such as through-feed systems or tunnel systems. The adhesive and coating-based products are characterized by their high quality and long-term stability. The business model of Dr Hoenle AG is based on the production of innovative products that are produced to the highest quality standards. The products are characterized by reliability, durability, and functionality. The company has extensive experience in the development of solutions and technologies and is therefore often chosen as a competent and reliable partner. The products are distributed internationally and customers can be found all over the world. Dr Hoenle AG has set itself the goal of constantly developing its products and technologies to meet the needs of customers. To achieve this, the company invests high amounts in research and development every year. Dr Hoenle AG also operates its own research laboratory and is constantly striving to drive forward new solutions and applications in various industries. In summary, Dr Hoenle AG is a renowned company with extensive experience in its industry. The company produces high-quality products and offers innovative solutions for a wide range of applications and industries. Thanks to research and development and the relentless search for new solutions, Dr Hoenle AG will also maintain its position as a leading company in global markets in the future. Dr Hoenle ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Dr Hoenle's Profit Margins
The profit margins of Dr Hoenle represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Dr Hoenle's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Dr Hoenle's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Dr Hoenle's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Dr Hoenle’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Dr Hoenle stock
How has the profit developed compared to last year?
The profit has increased by -86.65% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Dr Hoenle publish its earnings?
Dr Hoenle publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Dr Hoenle?
The profits of Dr Hoenle are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Dr Hoenle?
You can learn more about the earnings of Dr Hoenle by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Dr Hoenle pay?
Over the past 12 months, Dr Hoenle paid a dividend of 0.2 EUR . This corresponds to a dividend yield of about 2.22 %. For the coming 12 months, Dr Hoenle is expected to pay a dividend of 0.25 EUR.
What is the dividend yield of Dr Hoenle?
The current dividend yield of Dr Hoenle is 2.22 %.
When does Dr Hoenle pay dividends?
Dr Hoenle pays a quarterly dividend. This is distributed in the months of April, June, April, April.
How secure is the dividend of Dr Hoenle?
Dr Hoenle paid dividends every year for the past 0 years.
What is the dividend of Dr Hoenle?
For the upcoming 12 months, dividends amounting to 0.25 EUR are expected. This corresponds to a dividend yield of 2.8 %.
In which sector is Dr Hoenle located?
Dr Hoenle is assigned to the 'Industry' sector.
Wann musste ich die Aktien von Dr Hoenle kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Dr Hoenle from 3/29/2022 amounting to 0.2 EUR, you needed to have the stock in your portfolio before the ex-date on 3/25/2022.
When did Dr Hoenle pay the last dividend?
The last dividend was paid out on 3/29/2022.
What was the dividend of Dr Hoenle in the year 2023?
In the year 2023, Dr Hoenle distributed 0.2 EUR as dividends.
In which currency does Dr Hoenle pay out the dividend?
The dividends of Dr Hoenle are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Dr Hoenle stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital
Andere Kennzahlen von Dr Hoenle
Our stock analysis for Dr Hoenle Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dr Hoenle Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
